The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines Journal Article


Authors: Livingston, P. O.; Kaelin, K.; Pinsky, C. M.; Oettgen, H. F.; Old, L. J.
Article Title: The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines
Abstract: Seventeen patients with Stage II malignant melanoma were treated with vaccines prepared from three allogeneic melanoma cell lines in an attempt to induce a humoral immune response against melanoma cell surface antigens. The patients were free of detectable melanoma at the time of vaccination. Vaccines were prepared from three melanoma cell lines that expressed highly restricted melanocyte differentiation antigens. One of these cell lines also expressed an antigen found only on this particular line. The antigens were initially identified by antibodies in autologous serum; they were thus known to be recognized by the human immune system. In addition, two of the cell lines expressed HLA‐A, ‐B, ‐C, and ‐DR antigens; no HLA antigens were detectable on the third line. The vaccines were administered sequentially by subcutaneous injection, mixed with bacillus Calmette‐Guerin (BCG) or Corynebacterium parvum. The patients' sera were tested for antibodies against cell surface antigens of the vaccine cells in protein A assays and immune adherence assays, and the specificity of observed reactions was defined by absorption tests. Antibodies against alloantigens of the vaccine cells developed in 16 patients and in 15 patients, against antigens related to fetal calf serum in the culture medium. The magnitude of the antibody response to alloantigens varied considerably, with no difference between patients who received BCG or C. parvum with their vaccines. Antibodies against the restricted melanocyte differentiation antigens or the unique melanoma antigen expressed by the vaccine cells were not detected. Copyright © 1985 American Cancer Society
Keywords: adult; clinical article; middle aged; electron microscopy; bcg vaccine; cancer immunotherapy; melanoma; neoplasm proteins; cell line; in vitro study; histology; immune response; vaccination; melanoma cell; bacterial vaccines; antibodies, neoplasm; therapy; hla antigens; vaccine; antibody formation; vaccines; differentiation antigen; melanoma vaccine; subcutaneous drug administration; staphylococcal protein a; humans; human; male; female; priority journal; article; isoantibodies; propionibacterium acnes; immune adherence reaction
Journal Title: Cancer
Volume: 56
Issue: 9
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 1985-11-01
Start Page: 2194
End Page: 2200
Language: English
DOI: 10.1002/1097-0142(19851101)56:9<2194::Aid-cncr2820560910>3.0.Co;2-l
PUBMED: 4052966
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 26 October 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Herbert F Oettgen
    130 Oettgen
  2. Lloyd J Old
    593 Old